Berkshire Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36M | Buy |
593,856
+11,222
| +2% | +$654K | 1.54% | 28 |
|
|
2025
Q4 | $31.4M | Buy |
582,634
+38,329
| +7% | +$1.84M | 1.38% | 30 |
|
|
2025
Q3 | $24.5M | Sell |
544,305
-32,444
| -6% | -$1.52M | 1.04% | 35 |
|
|
2025
Q2 | $26.7M | Sell |
576,749
-3,821
| -0.7% | -$188K | 1.21% | 33 |
|
|
2025
Q1 | $27.2M | Sell |
580,570
-3,280
| -0.6% | -$191K | 1.3% | 33 |
|
|
2024
Q4 | $34.8M | Sell |
583,850
-25,487
| -4% | -$1.42M | 1.65% | 26 |
|
|
2024
Q3 | $25.3M | Hold |
609,337
| – | – | 1.29% | 31 |
|
|
2024
Q2 | $25.3M | Sell |
609,337
-26,936
| -4% | -$1.21M | 1.26% | 32 |
|
|
2024
Q1 | $34.5M | Buy |
636,273
+38,921
| +7% | +$1.98M | 1.83% | 21 |
|
|
2023
Q4 | $30.7M | Sell |
597,352
-678
| -0.1% | -$35.6K | 1.75% | 23 |
|
|
2023
Q3 | $34.7M | Sell |
598,030
-7,206
| -1% | -$442K | 2.16% | 12 |
|
|
2023
Q2 | $38.7M | Buy |
605,236
+5,631
| +0.9% | +$378K | 2.3% | 13 |
|
|
2023
Q1 | $41.6M | Sell |
599,605
-2,635
| -0.4% | -$186K | 2.57% | 9 |
|
|
2022
Q4 | $43.3M | Buy |
602,240
+8,425
| +1% | +$635K | 2.78% | 8 |
|
|
2022
Q3 | $42.2M | Sell |
593,815
-4,196
| -0.7% | -$304K | 2.99% | 6 |
|
|
2022
Q2 | $46M | Buy |
598,011
+12,015
| +2% | +$915K | 3.01% | 6 |
|
|
2022
Q1 | $42.8M | Buy |
585,996
+11,827
| +2% | +$794K | 2.7% | 11 |
|
|
2021
Q4 | $35.8M | Sell |
574,169
-1,207
| -0.2% | -$70.8K | 2.18% | 17 |
|
|
2021
Q3 | $34M | Buy |
575,376
+6,882
| +1% | +$453K | 2.28% | 12 |
|
|
2021
Q2 | $38M | Buy |
568,494
+50,475
| +10% | +$3.29M | 2.57% | 9 |
|
|
2021
Q1 | $32.7M | Sell |
518,019
-36,362
| -7% | -$2.26M | 2.43% | 10 |
|
|
2020
Q4 | $34.4M | Buy |
554,381
+39,356
| +8% | +$2.42M | 2.65% | 9 |
|
|
2020
Q3 | $31.1M | Sell |
515,025
-49,397
| -9% | -$2.97M | 3% | 5 |
|
|
2020
Q2 | $33.2M | Buy |
564,422
+28,930
| +5% | +$1.73M | 3.05% | 6 |
|
|
2020
Q1 | $29.8M | Buy |
535,492
+3,293
| +0.6% | +$201K | 3.11% | 3 |
|
|
2019
Q4 | $34.2M | Sell |
532,199
-14,313
| -3% | -$820K | 2.9% | 4 |
|
|
2019
Q3 | $27.7M | Buy |
546,512
+539,802
| +8,045% | +$25.4M | 2.39% | 8 |
|
|
2019
Q2 | $304K | Buy |
6,710
+600
| +10% | +$27.9K | 0.03% | 176 |
|
|
2019
Q1 | $292K | Sell |
6,110
-41
| -0.7% | -$2.04K | 0.02% | 189 |
|
|
2018
Q4 | $320K | Buy |
6,151
+1,020
| +20% | +$54.8K | 0.03% | 171 |
|
|
2018
Q3 | $319K | Buy |
5,131
+298
| +6% | +$17.7K | 0.03% | 180 |
|
|
2018
Q2 | $267K | Sell |
4,833
-348
| -7% | -$18.8K | 0.03% | 181 |
|
|
2018
Q1 | $328K | Buy |
5,181
+41
| +0.8% | +$2.64K | 0.03% | 164 |
|
|
2017
Q4 | $315K | Sell |
5,140
-39
| -0.8% | -$2.44K | 0.03% | 168 |
|
|
2017
Q3 | $330K | Sell |
5,179
-35
| -0.7% | -$2.04K | 0.04% | 153 |
|
|
2017
Q2 | $291K | Sell |
5,214
-7,524
| -59% | -$409K | 0.03% | 159 |
|
|
2017
Q1 | $693K | Buy |
12,738
+7,500
| +143% | +$411K | 0.08% | 110 |
|
|
2016
Q4 | $306K | Sell |
5,238
-79
| -1% | -$4.32K | 0.04% | 147 |
|
|
2016
Q3 | $287K | Sell |
5,317
-680
| -11% | -$43.7K | 0.04% | 148 |
|
|
2016
Q2 | $441K | Sell |
5,997
-6
| -0.1% | -$424 | 0.07% | 124 |
|
|
2016
Q1 | $383K | Buy |
6,003
+272
| +5% | +$17.2K | 0.06% | 115 |
|
|
2015
Q4 | $394K | Buy |
5,731
+1,673
| +41% | +$111K | 0.07% | 111 |
|
|
2015
Q3 | $240K | Hold |
4,058
| – | – | 0.04% | 137 |
|
|
2015
Q2 | $270K | Buy |
4,058
+700
| +21% | +$46.1K | 0.05% | 141 |
|
|
2015
Q1 | $217K | Buy |
+3,358
| New | +$210K | 0.04% | 151 |
|
Other funds holding BMY
VCM
VPM
Berkshire Asset Management's BMY Position: Q1 2026 in Review
Berkshire Asset Management increased its Bristol-Myers Squibb (BMY) stake by 1.9% in Q1 2026, buying an estimated $654K and bringing the position to 593,856 shares worth $36M. The position accounts for 1.54% of the portfolio, ranked #28.
Berkshire Asset Management first reported a position in BMY in Q1 2015 and has held it in 45 quarters since. The position peaked at $46M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Berkshire Asset Management held 593,856 shares of Bristol-Myers Squibb worth $36M as of Q1 2026.
- Berkshire Asset Management bought 11,222 Bristol-Myers Squibb shares in Q1 2026, an estimated $654K.
- Bristol-Myers Squibb made up 1.54% of Berkshire Asset Management's portfolio in Q1 2026, its #28 holding.
- Berkshire Asset Management first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 45 quarters since.
- Berkshire Asset Management's Bristol-Myers Squibb position peaked at $46M in Q2 2022.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Berkshire Asset Management's 13F filing for Q1 2026, filed 11 May 2026.